Bears Chase Down Acadia Pharma After Surprise Alzheimer's Setback

Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark in a Phase 2 study. The post Bears Chase Down Acadia Pharma After Surprise Alzheimer's Setback appeared first on Investor's Business Daily.